Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer

• Autores: Alfredo Carrato Mena, A. Gómez, Pilar Escudero Emperador, Manuel Chaves Conde, Fernando Rivera Herrero, Eugenio Marcuello Gaspar, E. González Flores, Cristina Grávalos Castro, Manuel Constenla Figueiras, José Luis Manzano Mozo, Fernando Losa Gaspà, Joan Maurel Santasusana, R. Dueñas García, Bartomeu Massuti Sureda, Javier Gallego Plazas, Jorge Aparicio Urtasun, A. Antón Torres, Enrique Aranda Aguilar
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 15, Nº. 9, 2013, págs. 705-711
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose To evaluate the efficacy and safety profile of the combination of panitumumab and irinotecan every 3 weeks in a phase II trial as second-line treatment in patients with advanced wild-type (WT) K-RAS colorectal cancer (CRC).

    Methods Fifty-three patients received 9 mg/kg of panitumumab followed by 350 mg/m2 of irinotecan every 21 days until disease progression, unacceptable toxicity or consent withdrawal.

    Results Median age of patients included was 67 years. All patients had previously received 5-fluorouracil, 84 % oxaliplatin and 8 % irinotecan as first-line treatment. Patients received a median of five infusions of panitumumab and irinotecan. On an intention-to-treat analysis, 12 patients (23 %) achieved partial responses and 22 patients (41 %) achieved disease stabilization. Median progression-free survival and overall survival were 4.5 and 15.1 months, respectively. The most frequent treatment-related severe toxicities per patient were diarrhoea (35.8 %), followed by skin rash (32.1 %), asthenia (18.9 %) and neutropenia (13.2 %). A significant association between clinical response and incidence and grade of skin toxicity was observed (p = 0.0032).

    Conclusion This study shows that the administration of panitumumab plus irinotecan every 3 weeks is safe, active and feasible as second-line treatment in patients with advanced WT K-RAS CRC.